Breast Cancer, Male
7
0
2
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
14.3%
1 terminated out of 7 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
Study on the Progress of Breast Cancer Cases in Males and the Assessment of Relapse Risk
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient